Merck And Orion Announce Mutual Exercise Of Option To Convert Opevesostat Co-Commercialization Agreement Into An Exclusive Global License For Merck; Orion Now Eligible For Development Milestones Up To $30M, Regulatory Milestones Up To $625M, And Sales...
Merck And Orion Announce Mutual Exercise Of Option To Convert Opevesostat Co-Commercialization Agreement Into An Exclusive Global License For Merck; Orion Now Eligible For Development Milestones Up To $30M, Regulatory Milestones Up To $625M, And Sales...
默沙東和Orion宣佈互相行使選擇權，將Opevesostat共同商業化協議轉爲默沙東的全球獨家許可證；Orion現有資格獲得高達3000萬美元的開發里程碑，高達6.25億美元的監管里程碑和高達9.75億美元的銷售里程碑。
Merck And Orion Announce Mutual Exercise Of Option To Convert Opevesostat Co-Commercialization Agreement Into An Exclusive Global License For Merck; Orion Now Eligible For Development Milestones Up To $30M, Regulatory Milestones Up To $625M, And Sales Milestones Up To $975M
默沙東和獵戶座宣佈互相行使權利，將Opevesostat共同營銷協議轉換爲默克貨幣的獨家全球許可證；獵戶座現在有權獲得最高3000萬美元的開發里程碑、最高6.25億美元的監管里程碑以及高達9.75億美元的銷售里程碑
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。